NVCR News and Press, NovoCure Limited From 02/09/21

Delcath Systems develops drug/device combos to treat liver cancers. The company’s stock is underappreciated due to past clinical failures and a de-listing despite promising clinical data. Delcath updated the trial design for its lead product to address past issues around pa...

Timothy J. Scannell, President and Chief Operating Officer of Stryker Corporation, elected to board of directors Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Timothy J. Scannell, an experienced executive leader, was elected to Novocure’...

Cancer has typically been treated by either radiation, surgery, drugs. But Novocure (NASDAQ: NVCR) has developed a fourth paradigm, tumor treating fields, which can inhibit the growth of tumors by inhibiting tumor cell division. In this video from Motley Fool Live, recorded...

Shares of Novocure continue to trounce the overall markets return. The performance is justified as the company remains in the early innings of its growth ascendancy. The secret to the stellar gains is the Optune system - a novel system to help treat various forms of cancer via ele...

NovoCure (NVCR) sees Q4 revenue of $144.0 (+45% Y/Y) vs. a consensus $133.62M.Full year 2020 net revenues of $494.4M (+41% Y/Y).Asaf Danziger, Novocure’s CEO. “Through our clinical and product development efforts, we believe we are just beginning to unlock the potential of ...

Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019 Novocure to present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021 Fourth quarter and full...

Novocure (NASDAQ: NVCR) will participate virtually in the 39 th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 8:20 a.m. ...

The Swiss Federal Office of Public Health ((BAG)) has added Novocure's (NVCR) Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma ((GBM)), effective April 1, 2021.The List of Remedies and Eq...

Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The...

Novocure ([[NVCR]] +5.0%) has enrolled the first patient in its Phase 3 TRIDENT trial, in newly diagnosed glioblastoma testing the potential survival benefit of initiating Optune concurrent with radiation therapy. Optune is a noninvasive, antimitotic cancer treatment that delivers Tumor ...